Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah.
Biostatistics Coordinating Center, George Washington University, Washington, District of Columbia.
Am J Perinatol. 2024 May;41(S 01):e2710-e2716. doi: 10.1055/s-0043-1774312. Epub 2023 Sep 19.
This study aimed to evaluate whether there are genetic variants associated with adverse neurodevelopmental outcomes in extremely low birth weight (ELBW) infants.
We conducted a candidate gene association study in two well-defined cohorts of ELBW infants (<1,000 g). One cohort was for discovery and the other for replication. The discovery case-control analysis utilized anonymized DNA samples and evaluated 1,614 single-nucleotide polymorphisms (SNPs) in 145 genes concentrated in inflammation, angiogenesis, brain development, and oxidation pathways. Cases were children who died by age one or who were diagnosed with cerebral palsy (CP) or neurodevelopmental delay (Bayley II mental developmental index [MDI] or psychomotor developmental index [PDI] < 70) by 18 to 22 months. Controls were survivors with normal neurodevelopment. We assessed significant epidemiological variables and SNPs associated with the combined outcome of CP or death, CP, mental delay (MDI < 70) and motor delay (PDI < 70). Multivariable analyses adjusted for gestational age at birth, small for gestational age, sex, antenatal corticosteroids, multiple gestation, racial admixture, and multiple comparisons. SNPs associated with adverse neurodevelopmental outcomes with < 0.01 were selected for validation in the replication cohort. Successful replication was defined as < 0.05 in the replication cohort.
Of 1,013 infants analyzed (452 cases, 561 controls) in the discovery cohort, 917 were successfully genotyped for >90% of SNPs and passed quality metrics. After adjusting for covariates, 26 SNPs with < 0.01 for one or more outcomes were selected for replication cohort validation, which included 362 infants (170 cases and 192 controls). A variant in SERPINE1, which encodes plasminogen activator inhibitor (PAI1), was associated with the combined outcome of CP or death in the discovery analysis ( = 4.1 × 10) and was significantly associated with CP or death in the replication cohort (adjusted odd ratio: 0.4; 95% confidence interval: 0.2-1.0; = 0.039).
A genetic variant in SERPINE1, involved in inflammation and coagulation, is associated with CP or death among ELBW infants.
· Early preterm and ELBW infants have dramatically increased risks of CP and developmental delay.. · A genetic variant in SERPINE1 is associated with CP or death among ELBW infants.. · The SERPINE1 gene encodes the serine protease inhibitor plasminogen activator inhibitor..
本研究旨在评估极低出生体重(ELBW)婴儿是否存在与不良神经发育结局相关的遗传变异。
我们在两个明确的 ELBW 婴儿队列中进行了候选基因关联研究(<1,000g)。一个队列用于发现,另一个用于复制。发现病例对照分析利用匿名 DNA 样本,评估了炎症、血管生成、大脑发育和氧化途径中 145 个基因的 1,614 个单核苷酸多态性(SNP)。病例为 1 岁时死亡或在 18 至 22 个月时被诊断为脑瘫(CP)或神经发育迟缓(Bayley II 精神发育指数[MDI]或运动发育指数[PDI] < 70)的儿童。对照组为神经发育正常的幸存者。我们评估了与 CP 或死亡、CP、智力迟缓(MDI < 70)和运动迟缓(PDI < 70)综合结局相关的显著流行病学变量和 SNP。多变量分析调整了出生时的胎龄、小于胎龄、性别、产前皮质类固醇、多胎妊娠、种族混合和多次比较。选择与不良神经发育结局相关且 < 0.01 的 SNP 用于复制队列验证。在复制队列中成功复制的定义为 < 0.05。
在发现队列中,对 1013 名婴儿(452 例病例,561 例对照)进行了分析,其中 917 名婴儿成功进行了>90%的 SNP 基因分型,并通过了质量指标。调整协变量后,选择了 26 个 SNP,这些 SNP 中的一个或多个结果的 < 0.01 用于复制队列验证,其中包括 362 名婴儿(170 例病例和 192 名对照)。编码纤溶酶原激活物抑制剂(PAI1)的丝氨酸蛋白酶抑制剂 1(SERPINE1)中的一个变体与发现分析中的 CP 或死亡的综合结局相关( = 4.1×10),并且在复制队列中与 CP 或死亡显著相关(调整后的优势比:0.4;95%置信区间:0.2-1.0; = 0.039)。
SERPINE1 中的遗传变异与 ELBW 婴儿的 CP 或死亡有关,该基因参与炎症和凝血过程。
· 极早产和极低出生体重的婴儿 CP 和发育迟缓的风险显著增加。
· SERPINE1 基因中的一个遗传变异与 ELBW 婴儿的 CP 或死亡有关。
· SERPINE1 基因编码丝氨酸蛋白酶抑制剂纤溶酶原激活物抑制剂。